Table 1.
Summary of in vivo studies using phage–antibiotic combination against MDR P. aeruginosa.
| Infection Model | Bacteria | Phage Therapy | Antibiotic Combination | Outcome | Reference |
|---|---|---|---|---|---|
| Lung infection, mouse | P. aeruginosa MDR | PEV20 (106 PFU/mg) | Ciprofloxacin (0.33 mg) |
Reduced bacterial load by 5.9 log | [45] |
| Acute immunocompromised, mouse | P. aeruginosa MDR | Three-phage cocktail (109 PFU/mL) |
Alone or with Meropenem | Enhanced therapeutic protection against pulmonary infection | [43] |
| Cystic fibrosis zebrafish | P. aeruginosa (PA01) | Four-phage cocktail (300–500 PFU/embryo) | Ciprofloxacin (100 µL) |
Reduced embryos lethality | [44] |
| Dorsal wound, mouse | P. aeruginosa (PA01) | PAM2H cocktail (108 PFU/mL) | Ceftazidime | Synergistic reduction in bacterial burden | [18] |